For connective tissue diseases, the multiplex assay is designed to rapidly detect and identify up to 1275 disease markers per hour. Seamless, microarray-internal calibration and quality control as ...
EYSINS, Switzerland, Feb. 3, 2025 /PRNewswire/ -- AliveDx announces the receipt of IVDR-CE mark for its MosaiQ AiPlex ® CTDplus multiplex assay. The multiplex assay enables a syndromic approach, ...
EYSINS, Switzerland, Feb. 10, 2025 /PRNewswire/ — AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex ® Celiac Disease ...
With respect to assay development, quality assurance and, ultimately, clinical adoption, the primary subject of this review, these advantages are critical. Implicit with these advantages, TMAs enable ...
The study suggests that long-term monitoring and patient management are crucial after COVID-19. Study: Long-Term Risk of Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19.
Systemic autoimmune Rheumatic Diseases such as Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus, Systemic Sclerosis (also known as Scleroderma), Sjögren's syndrome, idiopathic inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback